Trexquant Investment’s Phathom Pharmaceuticals PHAT Stock Holding History

Trexquant Investment’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.89M	Sell	173,884 -119,421	-41%	-$1.36M	0.01%	1219
2026 Q1	$3.26M	Buy	293,305 +156,481	+114%	+$1.98M	0.02%	822
2025 Q4	$2.27M	Buy	136,824 +58,641	+75%	+$837K	0.02%	948
2025 Q3	$920K	Buy	+78,183	New	+$807K	0.01%	1176
2025 Q2	–	Sell	-398,751	Closed	-$2.5M	–	1797
2025 Q1	$2.5M	Buy	398,751 +20,114	+5%	+$122K	0.03%	788
2024 Q4	$3.07M	Buy	+378,637	New	+$4.69M	0.04%	699
2023 Q4	–	Sell	-58,825	Closed	-$610K	–	1708
2023 Q3	$610K	Buy	58,825 +40,524	+221%	+$556K	0.02%	933
2023 Q2	$262K	Buy	+18,301	New	+$211K	0.01%	1237
2022 Q4	–	Sell	-14,955	Closed	-$166K	–	1650
2022 Q3	$166K	Sell	14,955 -18,388	-55%	-$175K	0.01%	1230
2022 Q2	$281K	Buy	+33,343	New	+$343K	0.01%	1161
2021 Q1	–	Sell	-6,262	Closed	-$208K	–	1386
2020 Q4	$208K	Buy	+6,262	New	+$254K	0.02%	872

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Trexquant Investment's PHAT Position: Q2 2026 in Review

Trexquant Investment reduced its Phathom Pharmaceuticals (PHAT) stake by 41% in Q2 2026, selling an estimated $1.36M and leaving 173,884 shares worth $1.89M. The position accounts for 0.01% of the portfolio, ranked #1219.

Trexquant Investment first reported a position in PHAT in Q4 2020 and has held it in 11 quarters since. The position peaked at $3.26M in Q1 2026. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Trexquant Investment held 173,884 shares of Phathom Pharmaceuticals worth $1.89M as of Q2 2026.
Trexquant Investment sold 119,421 Phathom Pharmaceuticals shares in Q2 2026, an estimated $1.36M.
Phathom Pharmaceuticals made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1219 holding.
Trexquant Investment first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
Trexquant Investment's Phathom Pharmaceuticals position peaked at $3.26M in Q1 2026.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.